Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 565 | 72 | 489 |
| Samples | 283 | 47 | 234 |
| Peptides | 220 | 27 | 194 |
Function
FUBP1 · Far upstream element binding protein 1
The protein encoded by this gene is a single stranded DNA-binding protein that binds to multiple DNA elements, including the far upstream element (FUSE) located upstream of c-myc. Binding to FUSE occurs on the non-coding strand, and is important to the regulation of c-myc in undifferentiated cells. This protein contains three domains, an amphipathic helix N-terminal domain, a DNA-binding central domain, and a C-terminal transactivation domain that contains three tyrosine-rich motifs. The N-terminal domain is thought to repress the activity of the C-terminal domain. This protein is also thought to bind RNA, and contains 3'-5' helicase activity with in vitro activity on both DNA-DNA and RNA-RNA duplexes. Aberrant expression of this gene has been found in malignant tissues, and this gene is important to neural system and lung development. Binding of this protein to viral RNA is thought to play a role in several viral diseases, including hepatitis C and hand, foot and mouth disease. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 217 amino-acid changes on canonical ENST00000370768 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FUBP1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FUBP1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 0/42 0% | 10/612 2% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Melanoma | 3/210 1% | 26/1899 1% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 13/1390 1% |
| Colorectal Carcinoma | 6/143 4% | 34/3239 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 7/810 1% |
| Gastric Carcinoma | 5/74 7% | 14/1809 1% |
| Ovarian Carcinoma | 0/109 0% | 11/998 1% |
| Bladder Carcinoma | 2/58 3% | 8/956 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Burkitts Lymphoma | 0/32 0% | 2/196 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Other Solid Cancers | 0/94 0% | 10/1515 1% |
| Esophageal Squamous Cell Carcinoma | 5/51 10% | 10/2550 0% |
| Neuroendocrine Tumour | 2/154 1% | 2/577 0% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Glioma | 0/52 0% | 10/2127 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 7/1592 0% |
| Head and Neck Carcinoma | 0/85 0% | 7/1574 0% |
| Hepatocellular Carcinoma | 1/46 2% | 8/2210 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Breast Carcinoma | 1/144 1% | 10/3264 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Kidney Carcinoma | 2/85 2% | 4/1862 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Pancreatic Carcinoma | 1/89 1% | 3/1611 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
Mutation Distribution
Where FUBP1 is mutated · all tissues, split by cell line vs tissue
How many mutations in FUBP1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 565 mutations in FUBP1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|